b12 in tirzepatide What Color Is with B12? Compounded vs FDA-Approved Tirzepatide - 60mg | PeterMD

Streptozotocin-induced diabetes resulted in persistent hyperglycaemia, total body weight loss, impaired learning and memory

At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems

Payer contracting plays a key role in this market as brands compete for preferred formulary placement

The swing became especially visible in 2023, when nearly half of all T2D patients who began a GLP-1 did so within just one month of their diagnosis